These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28154879)

  • 21. The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma.
    Andersen JAS; Spatzek AD; Vilstrup MH; Grupe P; Hess S; Holdgaard PC; Bastholt L; Gerke O; Hildebrandt MG
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2342-2351. PubMed ID: 35129651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pelvic lymph node dissection in metastatic melanoma to the groin should not be abandoned yet.
    Faut M; Kruijff S; Hoekstra HJ; van Ginkel RJ; Been LB; van Leeuwen BL
    Eur J Surg Oncol; 2018 Nov; 44(11):1779-1785. PubMed ID: 30054111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of FDG-PET-CT is limited in initial staging of nodal metastasis for thin cutaneous melanoma.
    Cheng D; McNicoll CF; Kirgan D; Jones MS; Rivera MR; Doyle GM; De Guzman MD; Baynosa J; St Hill CR
    Am J Surg; 2021 Apr; 221(4):737-740. PubMed ID: 32354604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?
    Fuster D; Chiang S; Johnson G; Schuchter LM; Zhuang H; Alavi A
    J Nucl Med; 2004 Aug; 45(8):1323-7. PubMed ID: 15299056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG PET in early stage cutaneous malignant melanoma.
    McIvor J; Siew T; Campbell A; McCarthy M
    J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT.
    Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E
    J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients.
    Helvind NM; Weitemeyer MB; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
    Ann Surg Oncol; 2023 Apr; 30(4):2377-2388. PubMed ID: 36752970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma.
    Crippa F; Leutner M; Belli F; Gallino F; Greco M; Pilotti S; Cascinelli N; Bombardieri E
    J Nucl Med; 2000 Sep; 41(9):1491-4. PubMed ID: 10994727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of 18F-FDG PET/CT lower-limb imaging in patients with malignant cutaneous melanoma.
    Plouznikoff N; Arsenault F
    Nucl Med Commun; 2017 Dec; 38(12):1103-1108. PubMed ID: 28885538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma.
    Singh B; Ezziddin S; Palmedo H; Reinhardt M; Strunk H; Tüting T; Biersack HJ; Ahmadzadehfar H
    Melanoma Res; 2008 Oct; 18(5):346-52. PubMed ID: 18781133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
    Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
    Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of 18F-FDG PET/CT and ultrasound in staging of patients with malignant melanoma.
    Weber P; Arnold A; Hohmann J
    Medicine (Baltimore); 2022 Oct; 101(42):e31092. PubMed ID: 36281128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.
    García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
    Kumar R; Alavi A
    Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of Brain Metastases on Follow-up
    Nia ES; Garland LL; Eshghi N; Nia BB; Avery RJ; Kuo PH
    J Nucl Med Technol; 2017 Sep; 45(3):193-197. PubMed ID: 28705927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.